GlobeNewswire

Abeona Therapeutics Reports Preclinical Data Demonstrating Broad Therapeutic Potential of AIM™ Gene Therapy in Retinal Diseases at Association for Research in Vision and Ophthalmology Annual Meeting

Share

NEW YORK and CLEVELAND, May 01, 2019 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced that intravitreal administration of the Company’s novel AIM™ AAV204 capsid to non-human primates led to robust transgene expression in the inner and outer retina. These new preclinical data also support the potential use of intravitreal administration to deliver gene therapy in an out-patient setting for a wide range of inherited and acquired retinal diseases. Findings were presented at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting in Vancouver.

“The broad retinal tropism of the AIM™ AAV204 capsid in non-human primates underscores the potential of our platform to deliver gene therapy beyond inherited diseases, including treatment of acquired retinal disorders that may be currently underserved,” said Timothy J. Miller, Ph.D., President and Chief Scientific Officer. “Intravitreal administration of AAV gene therapy, which does not require surgery, could potentially be performed in an out-patient setting and may be a safer and less invasive approach.”

In the preclinical study, intravitreal administration of the novel AIM™ AAV204 capsid in non-human primates resulted in broad transgene expression in the peripheral retina as well as intense expression in the fovea 25 days post-administration. AAV204 also transduced photoreceptor cells in retinal explants and transduced the outer retina, with positive green fluorescent protein (GFP) expression.

The non-human primate data were complemented by findings from mice models, which identified AAV204 as one of three lead candidate AIM™ capsids that demonstrate robust transduction of retinal cells. The data in mice demonstrated that intravitreal administration resulted in broad retinal expression of AAV204 that penetrated to the photoreceptor and retinal pigmented epithelium (RPE) layers.

About the AIM™ Vector Platform
Abeona is developing the AIM™ Vector Platform: a next generation of adeno-associated virus (AAV) capsids for use in gene therapies. The AIM™ capsid library can utilize AAV biology to selectively target delivery of genetic payloads to the central nervous system, lungs, eye, muscle, liver and other tissues. AIM™ vectors are non-virus-producing and have shown the potential to evade the immune responses generated by exposure to naturally-occurring AAV vectors. The Company’s AIM™ library contains more than 100 capsids with tissue tropisms selected for their potential to target a wide range of organs and multiple routes of delivery.

About Abeona Therapeutics
Abeona Therapeutics Inc. is a clinical-stage biopharmaceutical company developing gene and cell therapies for serious diseases. The Company’s clinical programs include EB-101, its autologous, gene-corrected cell therapy for recessive dystrophic epidermolysis bullosa, as well as ABO-102 and ABO-101, novel AAV9-based gene therapies for Sanfilippo syndrome types A and B (MPS IIIA and MPS IIIB). The Company’s portfolio of AAV9-based gene therapies also features ABO-202 and ABO-201 for CLN1 disease and CLN3 disease, respectively. Its preclinical assets include ABO-401, which uses the novel AIM™ AAV vector platform to address all mutations of cystic fibrosis. Abeona has received numerous regulatory designations from the FDA and EMA for its pipeline candidates and is the only company with Regenerative Medicine Advanced Therapy designation for two investigational therapies (EB-101 and ABO-102). For more information, visit www.abeonatherapeutics.com.

Forward Looking Statement
This press release contains certain statements that are forward-looking within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and that involve risks and uncertainties.  These statements include statements regarding our pipeline including the potential for the AIM™ vector platform in the treatment of retinal diseases based upon pre-clinical data, and the company’s goals and objectives.  We have attempted to identify forward looking statements by such terminology as “may,” will,” “anticipate,” “believe,” “estimate,” “expect,” “intend,” and similar expressions.

Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, numerous risks and uncertainties, including but not limited to: continued interest in our rare disease portfolio, our ability to initiate and enroll patients in clinical trials, the impact of competition, the ability to secure licenses for any technology that may be necessary to commercialize our products, the ability to achieve or obtain necessary regulatory approvals, the impact of changes in the financial markets and global economic conditions, risks associated with data analysis and reporting, and other risks as may be detailed from time to time in the Company’s annual reports on Form 10-K and quarterly reports on Form 10-Q and other reports filed by the Company with the Securities and Exchange Commission.  The Company undertakes no obligation to revise the forward-looking statements or update them to reflect events or circumstances occurring after the date of this presentation, whether as a result of new information, future developments or otherwise, except as required by the federal securities laws.

Investor Contact:
Sofia Warner
Senior Director, Investor Relations
Abeona Therapeutics
+1 (646) 813-4710
swarner@abeonatherapeutics.com

Media Contact:
Scott Santiamo
Director, Corporate Communications
Abeona Therapeutics
+1 (718) 344-5843
ssantiamo@abeonatherapeutics.com

About GlobeNewswire

GlobeNewswire
GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://globenewswire.com

GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire

Subscribe to all the latest releases from GlobeNewswire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire

MSAB: Continued investment for growth19.7.2019 08:00:00 CESTPress release

January - June Net sales increased 1.6 percent to SEK 130.4 (128.3) million (-4 percent in local currencies). EBIT amounted to SEK -17.1 (3.8) million. The EBIT margin was -13.1 (3.0) percent. Profit after tax amounted to SEK -15.3 (5.7) million. Earnings per share amounted to SEK -0.83 (0.31). Cash flow from operating activities amounted to SEK -6.2 (-11.1) million. Cash and cash equivalents and short-term investments amounted to SEK 52.5 (80.4) million at the end of the period. Second quarter Net sales increased 1.7 percent to SEK 64.1 (63.0) million (-4 percent in local currencies). EBIT amounted to SEK -11.4 (0.1) million. The EBIT margin was -17.8 (0.2) percent. Profit after tax amounted to SEK -10.8 (1.3) million. Earnings per share amounted to SEK -0.58 (0.07). Cash flow from operating activities amounted to SEK 0.7 (-11.4) million. Comments from the CEO Sales amounted to SEK 130.4 (128.3) million for the first six months of the year. EBIT came in at SEK -17.1 (3.8) million, the

MSAB: Fortsatta satsningar för tillväxt19.7.2019 08:00:00 CESTPressemelding

Januari - juni Nettoomsättningen ökade med 1,6 procent till 130,4 (128,3) mkr (-4 procent i lokala valutor) Rörelseresultatet uppgick till -17,1 (3,8) mkr Rörelsemarginalen uppgick till -13,1 (3,0) procent Resultat efter skatt uppgick till -15,3 (5,7) mkr Resultat per aktie uppgick till -0,83 (0,31) kr Kassaflöde från den löpande verksamheten uppgick till -6,2 (-11,1) mkr Likvida medel och kortfristiga placeringar uppgick vid periodens utgång till 52,5 (80,4) mkr Andra kvartalet Nettoomsättningen ökade med 1,7 procent till 64,1 (63,0) mkr, (-4 procent i lokala valutor) Rörelseresultatet uppgick till -11,4 (0,1) mkr Rörelsemarginalen uppgick till -17,8 (0,2) procent Resultat efter skatt uppgick till -10,8 (1,3) mkr Resultat per aktie uppgick till -0,58 (0,07) kr Kassaflöde från den löpande verksamheten uppgick till 0,7 (-11,4) mkr VDs kommentarer Omsättningen uppgick till 130,4 (128,3) mkr för årets första sex månader. Rörelseresultatet blev -17,1 (3,8) mkr, det försämrade resultatet är

Kinnevik:Interim Report 1 January - 30 June 201919.7.2019 08:00:00 CESTPress release

”It was an eventful second quarter, during which we focused our efforts on continuing the shift in our portfolio towards growth companies. These efforts included supporting high-performers in our private portfolio, evaluating our Millicom stake and supporting the IPO of Global Fashion Group.” Georgi Ganev, CEO of Kinnevik KEY PORTFOLIO DEVELOPMENTS Global Fashion Group began trading on the Frankfurt Stock Exchange on 2 July. The company raised a total of c. EUR 200m, of which EUR 60m from Kinnevik, to fuel continued growth Livongo announced its intention to go public at a proposed price range corresponding to a fully diluted pre-money valuation of USD 2.1-2.4bn. Kinnevik has agreed to purchase additional shares at the IPO price from one of Livongo’s investors, and we have also indicated our interest in purchasing newly issued shares in the IPO INVESTMENT MANAGEMENT ACTIVITIES Total investments of SEK 1,367m during the quarter, whereof SEK 632m in GFG, SEK 336m in Kolonial, SEK 156m in

Kinnevik:Delårsrapport 1 januari - 30 juni 201919.7.2019 08:00:00 CESTPressemelding

” Det har varit ett händelserikt andra kvartal, under vilket vi har fortsatt arbetet med att vikta om vår portfölj till en större andel tillväxtbolag. Detta har gjorts bland annat genom att stötta högpresterande bolag i vår privata portfölj, utvärdera vårt ägande i Millicom, samt genom att stötta börsnoteringen av Global Fashion Group. ” Georgi Ganev, Kinneviks vd VIKTIGA HÄNDELSER I PORTFÖLJEN Global Fashion Group började handlas på Frankfurtbörsen 2 juli. I samband med börsintroduktionen genomförde bolaget en nyemission om cirka 200 MEUR varav 60 MEUR från Kinnevik, i syfte att driva fortsatt tillväxt Livongo har meddelat att man avser börsnoteras med ett tilltänkt prisintervall som motsvarar en värdering på fullt utspädd basis om 2,1-2,4 MdUSD före emission av nya aktier i samband med börsnoteringen. Kinnevik har kommit överens om att köpa aktier från en av Livongos investerare till det slutliga priset i noteringen, och vi har även meddelat vårt intresse av att köpa ytterligare nyem

Huhtamäki Oyj’s Half-yearly Report January 1–June 30, 2019: Strong net sales growth and solid profitability19.7.2019 07:30:00 CESTPress release

HUHTAMÄKI OYJ HALF-YEARLY REPORT 19.7.2019 AT 8:30 Huhtamäki Oyj’s Half-yearly Report January 1–June 30, 2019: Strong net sales growth and solid profitability Q2 2019 in brief Net sales grew to EUR 867 million (EUR 786 million) Adjusted EBIT was EUR 78 million (EUR 71 million); reported EBIT EUR 78 million (EUR 80 million) Adjusted EPS was EUR 0.51 (EUR 0.46); reported EPS EUR 0.51 (EUR 0.54) Comparable net sales growth was 6% at Group level and 7% in emerging markets Currency movements had a positive impact of EUR 25 million on the Group’s net sales and EUR 2 million on EBIT H1 2019 in brief Net sales grew to EUR 1,669 million (EUR 1,511 million) Adjusted EBIT was EUR 146 million (EUR 131 million); reported EBIT EUR 145 million (EUR 141 million) Adjusted EPS was EUR 0.95 (EUR 0.86); reported EPS EUR 0.95 (EUR 0.93) Comparable net sales growth was 5% at Group level and 7% in emerging markets Currency movements had a positive impact of EUR 44 million on the Group’s net sales and EUR 4 m

Sinch AB (publ): Delårsrapport januari – juni 201919.7.2019 07:30:00 CESTPressemelding

Delårsrapport januari – juni 2019 April – juni 2019 Nettoomsättningen ökade med 18 procent till 1 176,7 MSEK (997,4). Den organiska tillväxten i lokal valuta var 15 procent. Bruttoresultatet ökade med 29 procent till 321,1 MSEK (248,6). Den organiska tillväxten i lokal valuta var 26 procent. Justerad EBITDA2 ökade med 17 procent till 114,2 MSEK (97,4). Justerad EBIT3 uppgick till 104,1 MSEK (91,2). Kvartalets resultat efter skatt uppgick till 53,3 MSEK (29,0). Resultat per aktie efter utspädning uppgick till 0,98 SEK (0,54). Januari – juni 2019 Nettoomsättningen ökade med 23 procent till 2 278,4 MSEK (1 856,0). Den organiska tillväxten i lokal valuta var 16 procent1. Bruttoresultatet ökade med 36 procent till 610,6 MSEK (448,6). Den organiska tillväxten i lokal valuta var 24 procent1. Justerad EBITDA2 ökade med 39 procent till 226,4 MSEK (162,3). Justerad EBIT3 uppgick till 206,3 MSEK (149,9). Periodens resultat efter skatt uppgick till 111,1 MSEK (38,3). Resultat per aktie efter utspä